| 项目编号 |
PRJCA023423 |
| 项目标题 |
Determinants of neoadjuvant response and resistance in advanced clear cell renal cell carcinoma |
| 涉及领域 |
Medical |
| 数据类型 |
Transcriptome or Gene expression
Single cell sequencing
|
| 物种名称 |
Homo sapiens
|
| 描述信息 |
With immunotherapy-based combination (ICB) has been recommended as first-line treatment for advanced RCC, Labbate et al. initially reported a case of complete response of an extensive vena cava tumor thrombus with neoadjuvant immunotherapy. Though the safety and feasibility has been confirmed by following studies, the evidence was based on case report and series. Due to high objective response rate of ICB than TKI in advanced RCC, we hypothesized that the ICB would yield a higher reduction in level of inferior vena cave tumor thrombus (IVC-TT). This Phase 2 pilot study evaluated the efficacy and safety of neoadjuvant toripalimab plus axitinib for RCC with IVC-TT. |
| 样品范围 |
Monoisolate |
| 发布日期 |
2025-08-19 |
| 出版信息 |
| PubMed ID |
文章标题 |
杂志名称 |
Doi |
发表年份 |
| 39362847
|
Neoadjuvant toripalimab plus axitinib for clear cell renal cell carcinoma with inferior vena cava tumor thrombus: NEOTAX, a phase 2 study
|
Signal Transduction and Targeted Therapy
|
10.1038/s41392-024-01990-2
|
2024
|
|
|
| 项目资金来源 |
| 机构 |
项目类型 |
授权项目ID |
授权项目名称 |
| National Natural Science Foundation of China (NSFC)
|
|
82341030
|
|
| National Natural Science Foundation of China (NSFC)
|
|
82173061
|
|
| National Natural Science Foundation of China (NSFC)
|
|
82372704
|
|
| National Natural Science Foundation of China (NSFC)
|
|
82373169
|
|
| PLA General Hospital "National Science Fund for Distinguished Young Scholars" Cultivation Foundation
|
|
No.202002
|
|
|
|
| 提交者 |
Weimin
ci (ciwm@big.ac.cn)
|
| 提交单位 |
Beijing Institute of Genomics, Chinese Academy of Sciences |
| 提交日期 |
2024-02-03 |
